Peak Bio Company Description

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.

The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.

Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD).

The company is based in Palo Alto, California.

Peak Bio, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	6

Contact Details

Address: 4900 Hopyard Road Pleasanton, Delaware Delaware United States
Phone	925-463-4800

Stock Details

Ticker Symbol	PKBO
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US70470P1084
SIC Code	2836

Key Executives

Name	Position
Dr. Hoyoung Huh M.D., Ph.D.	Executive Chairman
Divya Patel CPA	Acting Chief Financial Officer
Dr. Satyajit Mitra Ph.D.	Head of Oncology and Executive Director